All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

FDA approves Jazz Pharmaceuticals and PharmaMar's Zepzelca with Tecentriq for first-line maintenance extensive-stage small-cell lung cancer treatment
Small molecule, cancer, alkylating agent, small cell lung cancer, combination therapy, checkpoint inhibitor - Read more

THE GOOD
Business Development & Partnerships

Vaxcyte, Thermo Fisher strike $1B fill-finish manufacturing deal for pneumococcal vaccine pipeline
Manufacturing agreement, vaccine, infectious disease - Read more

Biomap, Legend Capital partner via BioGend Science for AI drug discovery pipeline development
AI/ML, drug discovery, co-development, antibody, joint venture - Read more

Sobi, Kinaxis partner on Maestro platform implementation for rare disease supply chain optimization
Supply chain partnership, rare disease, manufacturing, global, data analytics - Read more

C4 Therapeutics, Pfizer collaboration for Phase 1b cemsidomide-elranatamab combination trial in multiple myeloma
Clinical trial collaboration, oncology, bispecific antibody, protein degradation - Read more

OmniaBio, BrainChild Bio partner for CAR-T manufacturing in pediatric brain cancer trials
Manufacturing agreement, oncology, cell therapy, rare disease - Read more

George Medicines, Biolab Farmacêutica license GMRx2 hypertension treatment for Brazil commercialization with upfront fees and royalties
Licensing deal, cardiometabolic, small molecule, milestone payments, Brazil, commercialization - Read more

Saya Biologics, Maxigen Biotech partner to launch osteoarthritis treatments in Mexico
Commercialization, manufacturing agreement, hyaluronic acid therapy, osteoarthritis - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Amgen's Repatha PCSK9 inhibitor meets Ph3 primary prevention goals for cardiovascular events in landmark study
Antibody, cardiovascular, PCSK9 inhibitor, primary prevention, cholesterol-lowering - Read more

Anavex reports positive Ph2 results for ANAVEX3-71 targeting sigma-1 receptor in schizophrenia treatment
Small molecule, neurological, schizophrenia, sigma-1 receptor, neuroinflammation, GFAP biomarker - Read more

THE GOOD
Fundraises

Cartography raises $67M Series B, T cell engager for cancer treatment
Oncology, antibody, T cell engager, clinical-stage - Read more

Sernova raises $13M debt-to-equity conversion, Cell Pouch therapy for diabetes
Regenerative medicine, cell therapy, type 1 diabetes, clinical-stage - Read more

Predicta Biosciences raises $23.4M Series A, precision oncology diagnostic solutions
Precision oncology, diagnostic platform, blood cancers, multiple myeloma, biomarker discovery - Read more

OncoC4 raises $50M Series B, advancing cancer immunotherapy pipeline including PD-1/VEGF bispecific
Oncology, bispecific antibody, immunotherapy, clinical-stage - Read more

Cirrus Therapeutics raises $11M Seed, advancing ocular gene therapy for dry AMD
Gene therapy, ocular immunology, dry AMD, AAV platform - Read more

Leyden Labs raises €30M ($35.2M) equity funding, advancing nasal spray against respiratory viruses
Infectious disease, nasal spray, respiratory viruses, mucosal delivery, platform technology - Read more

THE GOOD
Investments

Daiichi Sankyo opens third international research institute in San Diego, expanding global R&D strategy
Strategic, operational, investment, research expansion - Read more

THE GOOD
Lawsuits

AbbVie, BeOne end BTK inhibitor patent lawsuit after USPTO invalidates AbbVie's patent claims
BTK inhibitor, oncology, strategic, competitive - Read more

Formycon, Klinge, Valorum settle Eylea biosimilar patent disputes with Regeneron, enabling 2026 U.S. launch
Biosimilar, ophthalmology, strategic, regulatory, settlement - Read more

Vanda, FDA settle legal disputes with expedited drug reviews following appeals court victory
Small molecule, sleep disorders, regulatory, strategic - Read more

THE GOOD
Marketing

e-therapeutics relaunches as Tangram Therapeutics, unveils LLibra OS AI platform for RNAi drug development
RNAi therapeutics, metabolic disease, strategic, operational, competitive - Read more

THE GOOD
Mergers & Acquisitions

Nanyang Biologics merges with SPAC RF Acquisition Corp for $1.5B Nasdaq listing
Small molecule, oncology, strategic, major transaction - Read more

PRESENTED BY YOU?
Get the attention of 2200+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Business Development & Partnerships

Galapagos receives non-binding offers for cell therapy business divestment from financial consortia, “limited” interest from other firms
Acquisition, cell therapy, divestment, financial investors - Read more

Metagenomi, Affini-T terminate gene editing partnership due to Affini-T's assignment for creditors
Licensing deal, oncology, gene therapy, cell therapy - Read more

THE BAD
Layoffs

Bolt halves workforce again, delays BDC-4182 immunotherapy readout to extend cash into 2027
Antibody drug conjugate, oncology, cost reduction, operational, financial - Read more

THE UGLY
Regulatory

No new BLAs or NDAs as FDA impacted by US government shutdown
Drug approval process, government shutdown - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here